Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

You searched for:

Slide 1 Updates in Colorectal Cancer Thomas Reske, MD PhD CMD AGFS FACP Associate Professor of Medicine LSUHSC New Orleans, LA Disclosure of Conflicts of Interest Thomas Reske, MD, has no real or apparent financial relationships to disclose. The following slides were shared by authors/presenters and permitted to be presented today. Biology …
6 accc-cancer.org | Vol 36, No. 1, 2021 | OI ACCC Joins Lawsuit Against MFN Final Rule BY CHRISTIAN G. DOWNS, JD, MHA On Friday, Nov. 20, 2020, the Centers for Medicare & Medicaid Services (CMS) released the Most Favored Nation (MFN) Model Interim Final Rule with Comment Period. The model is mandatory for all Medicare physicians, non-physician practitioners, supplier groups (such as group …
Holding up Home Care and Hospice Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=uacc20 Oncology Issues ISSN: 1046-3356 (Print) 2573-1777 (Online) Journal homepage: https://www.tandfonline.com/loi/uacc20 Holding up Home Care and Hospice Joy Stair To cite this article: Joy Stair (1998) Holding up Home …
JA09-First-Person
Accelerated Approvals Reconsidered None Changes in Dosing/Administration None Changes in Labeled Indications Xalkori® (crizotinib) – Pfizer received approval to market its kinase inhibitor for the treatment of adult and pediatric patients with ALK-positive unresectable, recurrent, or refractory inflammatory myofibroblastic tumor, a rare soft-tissue malignancy. The approval was …
Accelerated Approvals Reconsidered None Changes in Dosing/Administration None Changes in Labeled Indications Xalkori® (crizotinib) – Pfizer received approval to market its kinase inhibitor for the treatment of adult and pediatric patients with ALK-positive unresectable, recurrent, or refractory inflammatory myofibroblastic tumor, a rare soft-tissue malignancy. The approval was …
Accelerated Approvals Reconsidered None Changes in Dosing/Administration None Changes in Labeled Indications Xalkori® (crizotinib) – Pfizer received approval to market its kinase inhibitor for the treatment of adult and pediatric patients with ALK-positive unresectable, recurrent, or refractory inflammatory myofibroblastic tumor, a rare soft-tissue malignancy. The approval was …
MJ08-Xoft-Axxent-Electronic-Brachytherapy-A-New-Method-of-Delivering-Partial-Breast-Irradiation
ASCO Updates: Lung Cancer Maggie Byrne, MD, MS Assistant Professor University of Iowa Disclosures • None Outline Peri-operative NSCLC Abstract 8500: Surgical outcomes with resectable NSCLC receiving neoadjuvant nivolumab +/- relatlimab Abstract 8501: NEOTORCH: Peri-operative toripalimab with chemotherapy in resectable stage II-III NSCLC Adjuvant NSCLC with EGFR mutation …
Survivorship-A-Model-Cancer-Wellness-Program
ACCC and Quintiles Join Forces Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=uacc20 Oncology Issues ISSN: 1046-3356 (Print) 2573-1777 (Online) Journal homepage: https://www.tandfonline.com/loi/uacc20 ACCC and Quintiles Join Forces John E. Feldmann To cite this article: John E. Feldmann (2000) ACCC …
MA11-Providence-Oncology-&-Hematology-Care-Clinic-Westside
MA13-Action
FAN-Communication-with-Compassion
2020 ACCC Innovator Awards: Making Outpatient Chemo Possible August 6, 2020 To improve patient care and reduce overall costs, the University of Arizona Cancer Center at Banner University Medical Center in Tucson—ACCC Innovator Award winner— transitioned to delivering select chemotherapies in its ambulatory clinics. Doing so took a significant coordinated effort. The task of assessing which chemotherapies …
ASCO® DIRECT Highlights 2019: Cancer Genomics and Molecular Diagnostics Target Audience The primary target audience for this meeting comprise the multidisciplinary clinical cancer care team members including, but not limited to medical, surgical, and radiation oncologists; fellows; gastroenterologists; nephrologists; neurologists; pathologists; pulmonologists; radiologists; researchers; oncology …
Samantha R. Guild, JD, is the director of education, public policy, and patient services for AIM at Melanoma—the largest international melanoma foundation globally engaged and locally invested in advancing the battle against melanoma through innovative research, legislative reform, education, and patient and caregiver support. Ms. Guild is responsible for the development and implementation of AIM’s …
ASSOCIATION OF COMMUNITY CANCER CENTERS 1 An Innovative Approach to Navigating Patients Through Cancer Diagnostics ASSOCIATION OF COMMUNITY CANCER CENTERS W hen ACCC began its journey to explore how cancer programs and practices around the country are meeting the demands of increased precision medicine testing, the concept of precision medicine stewards—a nuanced approach …
ASSOCIATION OF COMMUNITY CANCER CENTERS 1 An Innovative Approach to Navigating Patients Through Cancer Diagnostics ASSOCIATION OF COMMUNITY CANCER CENTERS W hen ACCC began its journey to explore how cancer programs and practices around the country are meeting the demands of increased precision medicine testing, the concept of precision medicine stewards—a nuanced approach …
Live this week from the ACCC 40th National Oncology Conference (NOC), CANCER BUZZ interviews Steve Kennedy, Senior Vice President of Human Resources at Tennessee Oncology, about his session: Leadership Engagement and Sustainment During Challenging Times.